Cardiac risks in multimodal breast cancer treatment.
Budach
Wilfried
W
Department of Radiation Oncology, University of Düsseldorf, Germany. wilfried.budach@uni-duesseldorf.de
D018943:Anthracyclines / Q000009:adverse effects; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003630:Daunorubicin; D005260:Female; D005500:Follow-Up Studies; D006321:Heart / Q000528:radiation effects*; D006331:Heart Diseases / Q000139:chemically induced / Q000209:etiology*; D006801:Humans; D015201:Meta-Analysis as Topic; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D012306:Risk; D013997:Time Factors; D000068878:Trastuzumab
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab; D003630:Daunorubicin